Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
09/07/17GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO
PHILADELPHIA and OXFORD, United Kingdom, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) has exercised its option under a collaboration and license agreement signed in 2014 to exclusively license the right to research, develop, and commercialize Adaptimmune’s NY-ESO SPEAR T-cell therapy program. Further details will be provided in a conference call scheduled ... 
Printer Friendly Version
08/30/17Adaptimmune to Present at Upcoming CAR-TCR Summit; CEO James Noble to be a Keynote Speaker
PHILADELPHIA and OXFORD, U.K., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced its participation in the CAR-TCR Summit in Boston on Tuesday, September 5, and Wednesday, September 6 at the Seaport Hotel & World Trade Center; One Seaport Lane, Boston, MA 02210. The CAR-TCR summit highlights leaders in the CAR-T and TCR space to create a platform for cell immunotherapy expert... 
Printer Friendly Version
08/03/17Adaptimmune Reports Second Quarter 2017 Financial Results
– A registered direct offering in April combined with a public offering in March raised net proceeds of $103.2 million; operations funded through to late 2019 –        – Enrolling 9 clinical studies with NY-ESO as well as our wholly-owned assets (MAGE-A4, MAGE-A10, and AFP) across 12 different tumor indications – – On track for initial data from our wholly-owned assets in 2017 and 2018 –             – NY-ESO data presented at the Annual American Society of Clinical Oncology Meeting (ASCO) c... 
Printer Friendly Version
07/31/17Adaptimmune to Report Second Quarter 2017 Financial Results on August 3, 2017
PHILADELPHIA and OXFORD, United Kingdom, July 31, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer will announce financial results for the quarter ended June 30, 2017 before the open of the U.S. markets on Thursday, August 3, 2017. The Company will not be hosting a live teleconference this quarter. The press release will be available in the investor section of Adaptimmune’s corporate website at www.adaptimmune.com. About Adapti... 
Printer Friendly Version
07/13/17From the Desk of James Noble - Congratulations to Novartis on Winning FDA Panel Backing for its CAR T Therapy
On Tuesday July 12th, the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee (ODAC) unanimously endorsed Novartis’s anti-CD19 CAR-T therapy (tisagenlecleucel, “CTL019”). This was a significant milestone in realizing the promise of engineered T-cell therapy, and it is likely that engineered T-cells targeting CD19 could be the first gene therapy approved for human use in the U.S. This endorsement represents not only confidence in engineered T-cell therapy as an import... 
Printer Friendly Version
06/05/17Adaptimmune Announces an Oral Presentation on Data from NY-ESO Study in Synovial Sarcoma and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
PHILADELPHIA and OXFORD, United Kingdom, June 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation on updated data from its NY-ESO study in synovial sarcoma, as well as four trials in progress posters. The data were presented at the 2017 ASCO annual meeting in Chicago, Illinois. The Company will host a live teleconference and webcast slide presentation on June 6th from 8:00–9:00 AM EDT (1:00... 
Printer Friendly Version
05/26/17Adaptimmune Announces an Oral Presentation and Four Trials in Progress Posters at the American Society of Clinical Oncology (ASCO) Annual Meeting
PHILADELPHIA and OXFORD, United Kingdom, May 26, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced an oral presentation, as well as four trials in progress posters, at the 2017 ASCO annual meeting in Chicago, Illinois on June 2 through June 6, 2017. During an oral presentation scheduled for 1:15-1:27 PM CDT on June 5th, Dr. Sandra P. D’Angelo of the Memorial Sloan Kettering Cancer Center will present a full updat... 
Printer Friendly Version
05/25/17Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting NY-ESO in Combination with KEYTRUDA® (pembrolizumab) in Multiple Myeloma
PHILADELPHIA and OXFORD, United Kingdom, May 25, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated its study of NY-ESO SPEAR T‑cells targeting NY-ESO in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 inhibitor marketed by Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), in patients with multiple myeloma. This study is now open for enrollment. Thi... 
Printer Friendly Version
05/16/17Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
PHILADELPHIA and OXFORD, U.K., May 16, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its MAGE‑A4 SPEAR T-cell study in patients with multiple malignant solid tumors. This study is now open for enrollment. This is Adaptimmune’s third wholly-owned therapeutic candidate to enter clinical trials. The Company already has ongoing studies to evaluate its T-cell therapies target... 
Printer Friendly Version
05/10/17Adaptimmune Reports First Quarter 2017 Financial Results
– Offerings in March and April raised net proceeds of $103.2 million; operations funded through to late 2019 – – Initiated study with wholly-owned AFP SPEAR T-cells – – Initial data from three wholly-owned assets (MAGE-A4, MAGE-A10, and AFP) in up to eight tumor indications anticipated in 2017 and 2018 – – Updated NY-ESO data to be presented in an oral presentation at the upcoming Annual American Society of Clinical Oncology (ASCO) Meeting – PHILADELPHIA and OXFORD, U.K., May 10, 2017 (GLO... 
Printer Friendly Version
05/10/17Adaptimmune Announces Initiation of Study to Evaluate SPEAR T-Cell Therapy Targeting AFP in Liver Cancer
PHILADELPHIA and OXFORD, U.K., May 10, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated the first site for its AFP SPEAR T-cell study in patients with locally advanced or metastatic hepatocellular carcinoma, the sixth most common cancer worldwide. This study is now open for enrollment. This is Adaptimmune’s second wholly-owned therapeutic candidate to enter clinical trials. The Company alre... 
Printer Friendly Version
05/03/17Adaptimmune to Report First Quarter 2017 Financial Results on May 10, 2017
PHILADELPHIA and OXFORD, U.K., May 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the quarter ended March 31, 2017 before the open of the U.S. markets on Wednesday May 10, 2017. Following the announcement, the company will host a live teleconference and webcast at 8:00 a.m. EST (1:00 p.m. BST) on the same day at which time management will provide a business update and discuss the financial... 
Printer Friendly Version
05/02/17Adaptimmune to Present at Upcoming Deutsche Bank 42nd Annual Health Care Conference
PHILADELPHIA and OXFORD, U.K., May 02, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will be presenting at the Deutsche Bank 42nd Annual Health Care Conference on Thursday, May 4, 2017 at 1:10 PM EDT (6:10 PM BST). The conference is being held at the InterContinental Boston Hotel in Boston, MA. Adaptimmune’s presentation will be webcast live for investors ... 
Printer Friendly Version
04/10/17Adaptimmune Therapeutics plc Announces Closing of $42 Million Registered Direct Offering
PHILADELPHIA and OXFORD, U.K., April 10, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced registered direct offering of its American Depositary Shares (“ADSs”) following its entry into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”) to purchase an aggregate of approximately US$42,000,000 of its ADSs. Adaptimmune sold 7,000,000 ADSs... 
Printer Friendly Version
04/05/17Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom, April 05, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a definitive agreement with Matrix Capital Management Company, LP (“Matrix”) to purchase an aggregate of approximately US$42,000,000 of its American Depositary Shares (“ADSs”) in a registered direct offering. The transaction was completed from the company’s shelf registration ... 
Printer Friendly Version
03/27/17Adaptimmune to Participate in Upcoming Jefferies Immuno-Oncology Summit
PHILADELPHIA and OXFORD, United Kingdom, March 27, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, and Gwen Binder-Scholl, Adaptimmune’s Chief Technology Officer, will be participating on an expert panel regarding cell therapy in solid tumors at the Jefferies Immuno-Oncology Summit on Thursday, March 30, 2017 at 11:45 AM EDT (4:45 PM BST). The conference is ... 
Printer Friendly Version
03/27/17Adaptimmune Therapeutics plc Announces Closing of Public Offering and Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
PHILADELPHIA and OXFORD, UK, March 27, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”). Adaptimmune sold 15,700,223 ADSs at a price to the public of $4.20 per ADS, which included 1,400,223 ADSs sold pursuant to the exercise of the underwriters’ option to purchase up to 2,145,000 additiona... 
Printer Friendly Version
03/22/17Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom, March 22, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 14,300,000 of its American Depositary Shares (“ADSs”) at a price to the public of $4.20 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 2,145,000 ADSs at the public offer... 
Printer Friendly Version
03/21/17Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares
PHILADELPHIA and OXFORD, United Kingdom, March 21, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Adaptimmune also expects to gran... 
Printer Friendly Version
03/15/17Adaptimmune Broadens Executive Team
PHILADELPHIA and OXFORD, United Kingdom, March 15, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has broadened its executive team with the appointment of co-founder, Helen Tayton-Martin, Ph.D., M.B.A, to the newly-created role of Chief Business Officer, and Mr. William (Bill) Bertrand, Jr., J.D., as Chief Operating Officer. Both appointments are effective immediately. Adaptimmune has an unrivalled por... 
Printer Friendly Version
03/13/17Adaptimmune Reports Fourth Quarter and Full Year 2016 Financial Results
– Opened two new INDs for wholly-owned SPEAR® T-cell therapies; Company now has four open INDs in 11 indications – – Received orphan designation, PRIME regulatory support and Breakthrough Therapy designation for NY-ESO SPEAR T-cell – – Received FDA notification of permission to proceed with new cell manufacturing process – – Conference call to be held today at 8:00 a.m. EDT (12:00 p.m. GMT) – PHILADELPHIA and OXFORD, United Kingdom, March 13, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeu... 
Printer Friendly Version
03/08/17Adaptimmune to Report Fourth Quarter and Full Year 2016 Financial Results on March 13, 2017
PHILADELPHIA and OXFORD, United Kingdom, March 08, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, will announce financial results for the fourth quarter and full year ended December 31, 2016 before the open of the U.S. markets on Monday, March 13, 2017. Following the announcement, the company will host a live teleconference and webcast at 8:00 a.m. EDT (12:00 p.m. GMT) on the same day at which time management will provide a busi... 
Printer Friendly Version
03/02/17Adaptimmune to Present at the Cowen and Company 37th Annual Health Care Conference
PHILADELPHIA and OXFORD, United Kingdom, March 02, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday March 7, 2017 at 10:40-11:10 AM EST (3:40-4:10 PM GMT). The conference is being held at the Boston Marriott Copley Plaza. Adaptimmune’s presentation will be webcast live for inv... 
Printer Friendly Version
03/01/17Adaptimmune Cuts Ribbon on U.S. Headquarters at the Navy Yard in Philadelphia
Company Officially Opens Doors to New Base for Clinical and Manufacturing Operations PHILADELPHIA and OXFORD, United Kingdom, March 01, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc. (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced it will host a ribbon cutting ceremony this morning at 10:30am at the Navy Yard in Philadelphia to celebrate the opening of its newly constructed U.S. headquarters and base for clinical and manufacturing operations. Developed by Li... 
Printer Friendly Version
02/09/17Adaptimmune to Participate in Upcoming Investor Conference
PHILADELPHIA and OXFORD, U.K., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, Adaptimmune’s Chief Financial Officer, will present at the Leerink 6th Annual Global Healthcare Conference on Wednesday February 15, 2017 at 1:00 PM EST (6:00 PM BST). The conference is being held at the Lotte New York Palace Hotel. Adaptimmune’s presentation will be webcast live for investors through the... 
Printer Friendly Version
01/09/17Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target Collaboration
PHILADELPHIA and OXFORD, United Kingdom, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc (NYSE:GSK) (LSE:GSK) has nominated a second target, PRAME (preferentially expressed antigen in melanoma), under the strategic collaboration and licensing agreement between the companies. Adaptimmune will be responsible for PRAME preclinical TCR development and delivery of the IND package to GS... 
Printer Friendly Version
01/09/17Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development
PHILADELPHIA and OXFORD, United Kingdom, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Mark E. Dudley, Ph.D. has joined the company as Senior Vice President of Global Bio-Process and Development. Dr. Dudley has been a pioneer in the field of immunotherapy manufacturing, and has developed and implemented innovative early process design with accompanying analytics for multiple therapies. Prior to ... 
Printer Friendly Version
01/09/17Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
PHILADELPHIA and OXFORD, United Kingdom, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the US Food and Drug Administration (FDA) has accepted the Company’s investigational new drug (IND) application for autologous genetically modified T-cells expressing an affinity optimized T-cell receptor (TCR) specific for MAGE-A4 in patients with multiple malignant solid tumors. This will be Adaptimmune’s third... 
Printer Friendly Version